OKYO Pharma chair raises stake to 20.51%

OKYO Pharma Limited reported that its Chairman, Gabriele Cerrone, through Panetta Partners Ltd, acquired 25,000 ordinary shares at $1.40 per share.

Rhea-AI Filing Summary

OKYO Pharma Limited reported that its Chairman, Gabriele Cerrone, through Panetta Partners Ltd, acquired 25,000 ordinary shares at $1.40 per share. Following this purchase, his total holding is 10,851,416 ordinary shares, representing 20.51% of the company’s issued share capital.

The company is a clinical-stage biopharmaceutical business focused on neuropathic corneal pain (NCP) and anterior segment eye diseases. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP.

Filing Explained

A Form 6-K furnishes a foreign private issuer’s interim home-market information; this one reports the Chairman’s July 21 share purchase. The exhibit is furnished, not filed under Section 18, and incorporated by reference into the Form F-3 without changing the purchase’s completed state.

Key Figures

Incremental shares purchased: 25,000 ordinary shares Purchase price: $1.40 per share Total shares held by Chairman: 10,851,416 ordinary shares +2 more

5 metrics

Incremental shares purchased 25,000 ordinary shares Shares acquired by the Chairman through Panetta Partners Ltd

Purchase price $1.40 per share Price paid for the 25,000 ordinary shares

Total shares held by Chairman 10,851,416 ordinary shares Chairman’s total holding after the reported purchase

Ownership percentage 20.51% of issued share capital Proportion of OKYO’s issued share capital held by the Chairman

Planned trial size 111 patients Approximate enrollment for the planned global Phase 3 NCP trial

Key Terms

neuropathic corneal pain (NCP), anterior segment eye diseases, Phase 3 pivotal clinical trial, urcosimod, +1 more

5 terms

neuropathic corneal pain (NCP) medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

anterior segment eye diseases medical

"therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

Phase 3 pivotal clinical trial medical

"plans to initiate a global Phase 3 pivotal clinical trial in the second half"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

urcosimod medical

"evaluate a single-dose regimen of urcosimod for the treatment of NCP"

ordinary shares financial

"purchase of 25,000 ordinary shares at $1.40 per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did OKYO (OKYO) disclose?

OKYO disclosed that its Chairman, Gabriele Cerrone, via Panetta Partners Ltd, purchased 25,000 ordinary shares at $1.40 per share. This transaction increased his total holding to 10,851,416 ordinary shares, equal to 20.51% of the company’s issued share capital.

How much of OKYO (OKYO) does the Chairman now own?

After the latest purchase, the Chairman holds 10,851,416 ordinary shares of OKYO Pharma. This stake represents 20.51% of the issued share capital, giving him a significant ownership position in the company through Panetta Partners Ltd.

At what price were the new OKYO (OKYO) shares bought by the Chairman?

The Chairman purchased 25,000 OKYO ordinary shares at $1.40 per share. This incremental acquisition, made through Panetta Partners Ltd, raised his total ownership to 10,851,416 shares, equal to 20.51% of the company’s issued share capital.

What clinical trial plans did OKYO (OKYO) outline for NCP?

OKYO plans to start a global Phase 3 pivotal clinical trial in the second half of this year for neuropathic corneal pain. The trial will enroll approximately 111 patients to evaluate a single-dose regimen of urcosimod for this indication.

What therapeutic areas is OKYO (OKYO) currently focused on?

OKYO is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. Its lead program includes a planned global Phase 3 pivotal trial of urcosimod using a single-dose regimen for NCP.

On which market are OKYO (OKYO) shares listed and what type of shares are they?

OKYO’s ordinary shares are listed for trading on the Nasdaq Capital Market. The company describes itself as a clinical-stage biopharmaceutical business focused on developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/21/2026 - 07:01 AM Accepted by SEC EDGAR 07/21/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 21, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 25,000 ordinary shares at $1.40 per share, bringing his total holding to 10,851,416 ordinary shares, which is 20.51% of issued share capital.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: July 21, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated July 21, 2026

4

Exhibit 99.1

OKYO Pharma Announces Purchase of Shares by Chairman

London and New York, NY, July 21, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 25,000 ordinary shares at $1.40 per share, bringing his total holding to 10,851,416 ordinary shares, which is 20.51% of issued share capital.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 6.1 KB
• EX-99 GRAPHIC 4.4 KB